<DOC>
	<DOCNO>NCT02174900</DOCNO>
	<brief_summary>The purpose study evaluate tolerability safety increase dos primaquine combination artemether-lumefantrine G6PD deficient male asymptomatic P. falciparum malaria infection .</brief_summary>
	<brief_title>Safety Primaquine + Artemether-lumefantrine G6PD Deficient Males With Asymptomatic Malaria Infection ( SAFEPRIM )</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>1 . Male gender 2 . Age ≥18 year ≤45 year 3 . BMI ≥16 4 . P. falciparum parasitaemia density 5 . G6PD deficiency Beutler Fluorescent Spot test intervention group control group receive AL ( N=50 ) 6 . G6PD normal activity Beutler Fluorescent Spot test control group ( N=20 ) 7 . Informed consent participant 1 . Enrolled another clinical trial 2 . Fever &gt; 37.5°C ( tympanic ) history fever last 24 hour 3 . Evidence severe illness / danger sign active infection malaria 4 . Known allergy study medication 5 . Hb &lt; 11 g/dL 6 . Antimalarials take within last 2 week 7 . PQ take within last 4 week blood transfusion within last 90 day 8 . Nonfalciparum malaria coinfection 9 . Current use tuberculosis antiretroviral medication , sulphonamides , dapsone , nitrofurantoin , , nalidixic acid , ciprofloxacin , , methylene blue , toluidine blue phenazopyridine cotrimoxazole . 10 . History severe chronic illness</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>G6PD deficiency</keyword>
	<keyword>safety</keyword>
	<keyword>transmission</keyword>
</DOC>